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Stroke is a dynamic event in the brain involving heterogeneous cells. There is now compelling clinical evidence that prolonged,
moderate cerebral hypothermia initiated within a few hours after severe ischemia can reduce subsequent neuronal death and
improve behavioral recovery. The neuroprotective role of hypothermia is also well established in experimental animals. However,
the mechanism of hypothermic neuroprotection remains unclear, although, presumably involves the ability of hypothermia to
suppress a broad range of injurious factors. In this paper, we addressed this issue by utilizing comprehensive gene and protein
expression analyses of ischemic rat brains. To predict precise target molecules, we took advantage of the therapeutic time window
and duration of hypothermia necessary to exert neuroprotective eﬀects. We proposed that hypothermia contributes to protect
neuroinﬂammation, and identiﬁed candidate molecules such as MIP-3α and Hsp70 that warrant further investigation as targets
for therapeutic drugs acting as “hypothermia-like neuroprotectants.”
1.Introduction
Stroke is the second leading cause of death in the world [1],
andis aprimary causeof long-termdisability in adults[2,3].
One potential approach for treating acute stroke involves
neuroprotective agents. Although more than 100 clinical
trials of potential agents have been conducted, none of these
agents proved to be clinically eﬃcacious except for a free
radical scavenger edaravone [4–6]. However, recent progress
in understanding the disease have unveiled the cellular and
molecular events underlying ischemic cell death, such as loss
ofmetabolicstores,excessiveintracellularcalciumaccumula-
tion, oxidative stress, and neuroinﬂammatory response. For
instance, expression of stress, apoptosis, and inﬂammation-
related genes is known to be upregulated upon reperfusion
and reoxygenation [7, 8].
Therapeutic hypothermia is a promising neuroprotective
interventionshowntoimproveoutcomefrombrainischemia
in humans. The neuroprotective role of hypothermia has
been well established in experimental animals [9–11]
and in patients with cardiac arrest [12, 13]. Although
the key mechanism has not been clariﬁed, hypothermic
neuroprotection may provide insight into stroke pathology
and suggest novel therapeutic drug targets. To date, reactive
oxygen species production [14], NF-κBa c t i v a t i o n[ 15],
neutrophil inﬁltration [16] and cytochrome c release [17]
have been observed to be inhibited in hypothermia-treated
ischemic brains. However, it is diﬃcult to discern an
intrinsic hallmark of hypothermia from sequential outcomes
by retrospective approaches. To overcome this drawback,
we performed comprehensive gene and protein expression
analyses using ischemic brains with or without hypothermia
collected at appropriate time points. DNA microarray and
proteomic approaches are revolutionary technologies for
performance of high-throughput analyses of global gene
and protein expression. However, additional devises are
needed to elucidate the essential molecules and to identify
appropriate targets for therapeutic intervention from
massive amount of expression proﬁles. In this series of study,
we focused on the therapeutic time window and duration2 Stroke Research and Treatment
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Figure 1: An experimental strategy to identify potential drug
targets associated with hypothermia.
of hypothermia required for exerting neuroprotective eﬀects
(Figure 1).
2. Therapeutic Time Window and
Duration of Hypothermia
It is not known precisely when the series of events leading to
ﬁnal cell death and dissolution becomes irreversible. How-
ever, there is overwhelming evidence that the early recovery
phase, before the start of secondary deterioration, represents
the eﬀective window of opportunity for initiation of postin-
sultcooling[18].Acontinuouscomparisonofstrokedamage
withorwithouthypothermiawouldprovidemassiveamount
of information that would be diﬃcult to interpret precisely;
therefore, it is necessary to compare appropriate samples
according to the therapeutic time window and duration of
hypothermia required to exert a neuroprotective eﬀect. Pre-
cise control of brain temperature is critical for the evaluation
of the eﬃcacy of mild postischemic hypothermia and for
the acquisition of reproducible gene and protein expression
patterns. To predict the eﬀective phase of hypothermia,
we established a rat experimental stroke model: a 2-hr
transient intraluminal occlusion of the middle cerebral
artery (MCAO), which resulted in severe brain infarct with
almost complete striatal and extensive cortical damages, was
combined with a multichannel computer-controlled brain
temperature control system that enabled us to maintain a
constant brain temperature for more than 2 days [19]. Rats
were implanted with a telemetry brain temperature probe
with its temperature sensor inserted approximately 4mm
fromtheskullsurface(lowerlayerofthecerebralcortex).The
rats were individually housed in acrylic cages with wooden
chips. To induce hypothermia, each cage was placed in a
room maintained at 4◦C, and the cortical temperature was
continuously and individually monitored from the freely
moving rats. Cooling fans attached to the cage lid were
turned on when the brain temperature was higher than 35◦C
and were stopped when the brain temperature was below
34◦C. To maintain normothermia, rats were kept under
room temperature. Because the brain temperature increased
during MCAO, the term “normothermia” does not refer to
a certain controlled temperature. For instance, in our rat
model, normothemic rat brain temperature increased over
38◦C for more than 18hr [19]. Similar brain temperature
control systems that used water sprays for cooling instead
of cold rooms have been reported [20, 21]. The surgical
placement of the temperature probes into the brain on the
day prior to MCAO should be taken into consideration
during further experimentation because the stab wounds
might have had a preconditioning eﬀect. The therapeutic
timewindowisconsideredtodependupontheseverityofthe
insult, depth of damage, and duration of cooling [22–24].
We identiﬁed the therapeutic time window of mild
hypothermia at 35◦C in rats subjected to hypothermia after a
2-hrMCAO[19].Thebraininfarctvolumesmeasured2days
after MCAO were 288.6 ± 21.5mm 3 in normothermic rats.
In contrast, postischemic hypothermia signiﬁcantly reduced
the volume when introduced at 0hr (120.0 ± 21.7mm 3, P<
.005), 2hr (147.0 ± 26.3mm 3, P<. 005), and 4hr (209.9 ±
33.5mm 3, P<. 025) after normothermic reperfusion.
No signiﬁcant reduction was observed when postischemic
hypothermia was introduced 6hr after reperfusion (244.3 ±
35.5mm 3). The therapeutic time window of hypothermia
was therefore concluded as 4hr after reperfusion in our
model. However, even 4hr of hypothermia when introduced
immediately after reperfusion did not signiﬁcantly reduce
brain infarct volumes (182.3 ± 29.4mm 3)a sc o m p a r e dt o
the volumes in normothermic rats (219.3 ± 29.9mm 3). The
infarct volume after 24hr of hypothermia (63.1±28.2mm 3)
was signiﬁcantly smaller than that after normothermia
(219.2 ± 39.7mm 3, P<. 01), suggesting that hypothermia
should be maintained for longer than 4hr in our model to
obtainneuroprotectiveeﬀects.Thisﬁndingisconsistentwith
reports that mention the importance of prolonged hypother-
mia for persistent neuroprotection [25, 26]. Hypothermia
may exert neuroprotective eﬀects in ischemic brains by
regulating particular injurious factors within speciﬁc time
intervals.
3.DNA MicroarrayAnalysis
DNA microarray analysis is a useful tool for determining
gene expression [27–29]. A number of endogenous proteins
have been reported to be induced during ischemia, including
several involved in inﬂammation and neuronal death such
as the MAP kinase protein and heat shock proteins (HSP)
thatplayrolesinbothtissuedamageandreorganization[30–
35]. Lu et al. [36] reported upregulation of immediate early
genes,transcriptionfactors,andHSPsasearlyas30minafter
MCAO in 30min or 2hr transient rat MCAO models, and
upregulation of genes related to inﬂammation, apoptosis,
thecytoskeleton,andmetabolismthatpeakedwithin4–24hr
after MCAO. Figure 2 shows expression patterns of severalStroke Research and Treatment 3
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Figure 2: Stress-related genes expression in rat brains after reperfusion under normothermia. The expression levels of each mRNA in
ischemic core (red), penumbra (purple), and normal (yellow) regions were quantiﬁed by real-time PCR, and their mRNA expression levels
were shown as a gene copy number per 1ng of polyA+ RNA. The procedure used has been previously described [17].
stress-related genes after reperfusion in ischemic brains
of our rat model under normothermia. The expression
level of c-Fos mRNA reached the peak during MCAO and
sustained at least for 1h after reperfusion. Hsp70 mRNA
expression was also high in the beginning of reperfusion.
Interestingly,tumornecrosisfactor-α(TNF-α),interleukine-
1β (IL-1β), inducible nitric oxide synthase (iNOS), and IL-
6 mRNAs were transiently and sequentially induced after
reperfusion. In contrast, monocyte chemotactic protein-
1( MCP-1), transforming growth factor-β (TGF-β), and
p53 mRNAs gradually increased along with progression
of the disease. Gene expression analysis provides a large
amount of information regarding expression changes of
thousands of genes, and time-dependent changes should
therefore be analyzed to grasp the entire picture. Hence, the
information of therapeutic time window and time duration
of hypothermia was exploited. The therapeutic time window
of hypothermia in our model was 4hr, so we hypothesized
that gene expression changes occurring prior to this time
point are important for hypothermic neuroprotection. Of
the 8000 transcripts represented on the Aﬀymetrix Rat
U34A GeneChip, 45 ± 8% showed a present call (a speciﬁc
signal with statistical signiﬁcance) in both hypothermia
and normothermia brains during the 4hr reperfusion [19].
Approximately 400 of the genes were upregulated more
than 2-fold, but no genes were reproducibly suppressed.4 Stroke Research and Treatment
Of the upregulated genes, 22 were upregulated more than
20-fold, including Hsp70 mRNA. Interestingly, most of the
genes whose expression was signiﬁcantly suppressed by
hypothermia were inﬂammatory-related molecules includ-
ing IL-1β and osteopontin (OPN), suggesting that the
suppression of neuroinﬂammation primarily contributes to
neuroprotection. OPN has a proinﬂammatory role in some
diseases [37–40], although the neuroprotective role of OPN
is also reported [41]. Further studies are needed to elucidate
the roles of OPN in ischemic pathophysiology.
Meanwhile, we also speculated that the interruption of
hypothermia is implicated in ischemic damage because the
duration necessary to exert hypothermic neuroprotection
was longer than 4hr. To identify genes involved in the recov-
ery phase before the secondary deterioration, we compared
gene expression in ischemic brains kept in hypothermia for
8hr during reperfusion with those kept in hypothermia for
the ﬁrst 4hr followed by 4hr normothermia. We identiﬁed
12 genes functionally related to neuroinﬂammation, includ-
ing c-Fos, early growth response 1 and 4 (Egr-1, and Egr-4),
MAPK phosphatase-1 (MKP-1), macrophage inﬂammatory
protein-3α (MIP-3α), MCP-1,a n dIL-1β [19]. Egr-1 is a
master switch activated by ischemia to trigger the expression
of pivotal regulators of inﬂammation, such as IL-1β,M C P -
1, and macrophage inﬂammatory protein-2 (MIP-2), in
addition to coagulation and vascular hyperpermeability
[43]. Deng et al. [44] demonstrated that postischemic mild
hypothermia decreases inﬂammatory responses by suppress-
ing intercellular adhesion molecule-1 (ICAM-1), an essential
molecule for peripheral leucocyte recruitment into brain
parenchyma. Stroke-mediated release of proinﬂammatory
cytokines and adhesion molecules is a relevant component
of the complex pathophysiological response [45]. Those
inﬂammatory mediators enable leukocytes to adhere to the
vascular endothelial cells and to inﬁltrate inﬂammatory cells
from the circulation into the ischemic brain within hours
after ischemic damage. Studies addressing eﬃcacy of mild
hypothermia also indicate the importance of microglia acti-
vation [16, 44], nuclear-factor kappaB (NF-κB) activation
[46], or nitric oxide production [47].
4.ProteomicAnalysis
Proteomic analysis is another powerful tool for examining
the physiopathologies of diseases. Hence, proteomic studies
using brain tissues, blood, or cerebrospinal ﬂuids of stroke
patients [48] or experimental models [42, 49]h a v eb e e np e r -
formedtoelucidatethepathogenesisofstrokeandtoidentify
novel diagnostic biomarkers. Proteomic proﬁling generally
consists of 2 technologies: two-dimensional polyacrylamide
gelelectrophoresis(2D-PAGE)forthecomparisonofprotein
expression and LCQ-advantage micro-LC/MS/MS system
for protein identiﬁcation. In our experiments, the criteria
for altered protein expression between hypothermia and
normothermia were set as a ratio of greater than 1.5-
fold or less than 1/1.5-fold. Out of approximately 1200
spots on 2D-PAGE, 44 were identiﬁed with a statistically
signiﬁcant diﬀerence in mean values. Thirteen of the 44
spots were upregulated by hypothermia more than 1.5-fold
(1.50–1.85) compared with normothermia. Among them, a
spot identiﬁed as Hsp70 was studied further because it was
upregulatedbyMCAOandwasfurtherinducedbyhypother-
mia, although hypothermia itself did not induce Hsp70
in nonischemic brains [50]. This observation was con-
ﬁrmed by Hsp70-speciﬁc enzyme-linked immunosorbent
assay (ELISA), western blotting, and immunohistochemistry
of ischemic brain tissues. Hsp70 is a chaperone protein that
can fold or refold proteins, coordinate protein traﬃcking,
inhibit protein aggregation or degradation, and exhibit
antiapoptotic and anti-inﬂammatory activities under phys-
iological conditions [51–53]. Several reports have suggested
that Hsp70 inhibits NF-κB transcription by stabilizing NF-
κBandpreventingitsphosphorylation[54].Zhengetal.[55]
recently demonstrated that the interaction between Hsp70
and the NF-κB:IκB complex signiﬁcantly inhibits NF-κB
activation and leads to a decrease in NF-κB-regulated genes
in MCAO-treated Hsp70 transgenic mice. The expression of
Hsp70 and Hsp27 can be induced in glial cells and neurons
by a wide range of noxious stimuli including ischemia
[56, 57], epileptic seizure [58], and hyperthermia [59].
Neuroprotective eﬀects of Hsp70 against ischemic injury
have been reported for drugs that induce Hsp70 expression
[60] and in Hsp70 transgenic mice [61]. However, the
induction of Hsp70 by hypothermia has not been reported
to date. Hsp27 was also induced by ischemia, but was slightly
suppressedbyhypothermia(Figure 3).GAP43,aconstitutive
protein in the brain, and other Hsps, including Hsp40,
Hsp90, Grp78, Grp94, PDI, and ORP150, were detectable
under normal conditions and were not aﬀected by either
hypothermia or ischemia (Figure 3 and unpublished data).
Hence, Hsp70 accumulation by hypothermia was unique.
Recently Hagiwara et al. [62] reported that hypothermia at
34◦C increased the Hsp70 expression level in lipopolysac-
charide (LPS)-stimulated RAW264.7 cells, although IL-1β,
IL-6 and TNF-α expression levels were reduced under the
same conditions. In contrast to the protein level of Hsp70,
Hsp70 mRNA expression in our model was suppressed by
hypothermia. Rubtsova et al. [63] reported that the 5
 -
untranslated region of human Hsp70 mRNA represents an
internal ribosome entry site (IRES) with relative activity
similar to that of the classical picornaviral IRESs, implying
posttranscriptionalregulationofHsp70.Whileitisunknown
whether there is a similar IRES element in rat Hsp70 mRNA
and if the IRES is activated under hypothermia, this ﬁnding
merits further investigation because it hints at the identity of
neuroprotectants that increase Hsp70 by a novel mechanism.
The neuroprotective roles of Hsp70 in hypothermia are also
worthy of further investigation.
5. NovelTargetsforTherapeuticDrugsActingas
“Hypothermia-LikeNeuroprotectants”
Neuroinﬂammation is involved in the pathogenesis of many
CNS diseases. In stroke, excess inﬂammatory activation
results in brain injury and ultimately causes severe neu-
ronal apoptosis [64]. Anti-inﬂammatory therapies using
immunosuppressants [65] or biogenetics such as an anti-
ICAM-1-neutralizing antibody [66] have been applied inStroke Research and Treatment 5
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Figure 3: Eﬀect of occlusion of the middle cerebral artery (MCAO) and hypothermia on chaperones expression in rat brains. Western blot
analysis for Hsp70, Hsp27, Hsp40, Hsp90, ORP150, PDI, and GAD-43 was performed using protein samples from the penumbra and core
regions of rat ischemic brains at the indicated time points after reperfusion. GAD43 protein served as an internal control. N: normothermia,
H: hypothermia. “Con” denotes protein samples from normal rat brains. The procedure used has been previously described [42].
both preclinical and clinical contexts. MCP-1 is also con-
sidered a promising drug target due to its possible role in
exacerbatingischemicinjury,controllingblood-brainbarrier
permeability,anddrivingleukocyteinﬁltrationintothebrain
parenchymainstroke[67,68].OurDNAmicroarrayanalysis
revealed that both cerebral MIP-3α and CC-chemokine
receptor 6 (CCR6) genes were signiﬁcantly induced in the
core and penumbra regions of MCAO rat brains, and
hypothermia suppressed expression of both genes [69]. The
MIP-3α chemokine is expressed in macrophages, dendritic
cells, and lymphocytes. Depending on the conditions, MIP-
3α acts both constitutively and inducibly and serves as
a chemoattractant, especially in epithelial immunological
systems such as those of the skin and mucosa [70, 71]. In
CNS, MIP-3α expression has been reported in autoimmune
encephalomyelitis [72] and stroke [36, 73], but its full role
has not yet been determined. CCR6, the only receptor for
MIP-3α, is expressed in multiple leukocyte subsets, and
is implicated in diverse inﬂammatory responses in animal
models, such as allergic airway disorders, inﬂammatory
bowel disease, and autoimmune encephalitis [74, 75]. Strik-
ingly, intracerebral administration of an an anti-MIP-3α-
neutralizing antibody signiﬁcantly reduced infarct volumes
in MCAO rats (187.5 ± 37.0mm 3) compared with those
of vehicle (304.0 ± 32.8mm 3) and of control mouse IgG
(291.3±33.5mm 3), suggesting that MIP-3α-CCR6 signaling
is dominant in neuroinﬂammatory cascades involved in
brainischemia.Interestingly,MIP-3αadministrationintothe
striatum dose-dependently induced CCR6,b u tn o tCCR1 or
CCR2, gene expression. Intrastriatal injection of IL-1β and
TNF-α upregulated MIP-3α and CCR6 mRNA expression
levels in a sequential fashion. Robust induction of IL-1β and
TNF-α was observed at an acute phase of MCAO prior to
MIP-3α expression, suggesting that these cytokines may be
directly involved in MIP-3α production.
MIP-3α mRNA expression was markedly induced by
IL-1β and TNF-α in rat astrocytes but not in microglia
or neurons. Astrocytes are reported to emerge around the
damagedareaafterischemicinjury[76]andtoproduceMIP -
3α in a mouse experimental autoimmune encephalomyelitis
model [77]. In contrast, rat primary microglia constitutively
expresses the CCR6 gene in normal culture conditions while
astrocytes or neurons do not. Strikingly, the expression
of both iNOS and IL-1β were induced in MIP-3α-treated
microglia. Microglia are activated and accumulate around
the injured area following ischemia [78]. Because hypother-
mia reportedly inhibits NF-κB directly by decreasing IκB
kinase activity in MCAO rat brains [15], one of the
suppressiveeﬀectsofhypothermiaonMIP-3αinductionmay
beadirectinhibitionofNF-κBactivityinastrocytes.Another
possibility is that the upregulation of Hsp70 expression by
hypothermia inhibits MIP-3α expression by the interaction6 Stroke Research and Treatment
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Figure 4: A putative neuroinﬂammatory cascade exacerbated by MIP-3α-CCR6 signaling and protected by Hsp70 in ischemic rat brains.
In ischemic brains, the activation of neuroinﬂammatory cascades including MIP-3α-CCR6 signaling is speculated to progress as follows:
astrocytesactivatedbyproinﬂammatorycytokineslikeIL-1β andTNFαstimulateMIP-3αrelease.MIP-3αactivatesmicrogliathroughCCR6
and the cells produce other stress-related proteins like iNOS and IL-1β. Production of IL-1β further accelerates astrocyte activation. The self-
perpetuating neurotoxicity cascade may damage surrounding neurons and brain tissues. On the other hand, hypothermia suppresses the
cytokines and chemokines production in part by direct inhibition of NF-kB transcription via decreased IkB kinase activity. Our experiment
has also elucidated the potential eﬀect of hypothermia, which stimulated Hsp70 production in MCAO brains. Accumulated Hsp70 may
inhibit NF-kB transcription by directly interacting with the NF-kB:IkB complex in astrocytes and microglia.
of Hsp70 with the 5
 -untranslated regulatory region of MIP-
3α mRNA that contains NF-κB binding sites, as described by
Zheng et al. [55]. The activation of astrocytes and microglia
may accelerate brain injury-induced neuroinﬂammation via
MIP-3α-CCR6 signaling, whereas hypothermia would sup-
press this signaling via Hsp70-dependent and independent
pathways (Figure 4).
The physiological roles of MIP-3α-CCR6 signaling in
the CNS have yet to be fully determined, because various
roles of chemokines have recently been proposed in brain,
including as neurotransmitters and neuromodulators [79,
80]. The interactions between MIP-3α-CCR6 signaling and
other pathways involved in the ischemic pathology, such as
excitotoxicity, acidotoxicity, oxidative stress, and apoptosis,
also should be addressed. For instance, oxidative stress is
considered one of the primary risk factors that exacerbate
the damage by cerebral ischemia, and several components of
ROSaregeneratedafterischemia/reperfusioninjury[81].Kil
et al. [82] have reported that ROS production by leukocytes
and microglia in the ischemia brain is strongly suppressed by
hypothermia. Apoptosis is another important cause because
of the signiﬁcant contribution to the cell death subsequent
to ischemia/reperfusion injury [83]. Jong et al. [84]h a v e
reported the reduction in levels of matrix metalloproteinases
(MMPs) and increased expression of tissue inhibitor of
metalloproteinase (TIMP)-2 in response to mild hypother-
mia therapy in experimental stroke. Precise evaluation of
ROS, MMPs, and TIMPs in MCAO rat brains treated with
an anti-MIP-3α-neutralizing antibody may provide insights
into these interactions.
6. Conclusions
This paper described the utilization of current technologies
such as DNA microarray and proteomics to reveal the
speciﬁc mechanisms and key molecules involved in the neu-
roprotective eﬀects of hypothermia against ischemic injury.
The therapeutic time window and duration of hypothermia
necessary to exert neuroprotective eﬀects were determined
using a brain temperature control system. Comprehensive
gene expression analysis showed that suppression of neu-
roinﬂammatory cascades including MIP-3α-CCR6 signaling
may primarily contribute to the neuroprotective eﬀects of
hypothermia. In contrast, proteomics identiﬁed Hsp70 as
ap o t e n t i a le ﬀector. Although the physiological roles and
potential cross-talk between these molecules remain to be
elucidated, these approaches may be promising for the
discovery of antistroke pharmaceutical drug targets.
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